Clinical Trials Logo

Circulating Tumor DNA clinical trials

View clinical trials related to Circulating Tumor DNA.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT06404593 Completed - Colorectal Cancer Clinical Trials

Dynamic ctDNA Detection for Colorectal Cancer Liver Metastases

Start date: June 18, 2019
Phase:
Study type: Observational

Evaluating the value of dynamic monitoring of a colorectal cancer liver metastasis cohort underwent curative resection after receiving multipoint ctDNA detecting in predicting recurrence prognosis and guiding adjuvant chemotherapy treatment.

NCT ID: NCT05427617 Completed - Clinical trials for Metastatic Breast Cancer

Circulating Tumor DNA (ctDNA)-Guided Late-Line Treatment in Patients With Late-Stage Breast Cancer

ACTDNAGLT
Start date: December 1, 2016
Phase:
Study type: Observational

This is a retrospective, observational, multi-center clinical study of circulating tumor DNA (ctDNA) to guide late-line therapy in late-stage metastatic breast cancer patients.

NCT ID: NCT05415787 Completed - Clinical trials for Metastatic Prostate Cancer

Evaluation of the Technical Feasibility of Testing ct DNA for Homologous Recombination Gene Variants in Metastatic Prostate Cancer.

PROMECI
Start date: August 18, 2022
Phase:
Study type: Observational

Evaluation of technical feasibility for Homologous Recombination (HR) genes variants research on circulating tumor DNA (ctDNA) from plasma and urine of patients with a metastatic prostate cancer.

NCT ID: NCT05079074 Completed - Clinical trials for Metastatic Breast Cancer

Clinical Application of Circulating Tumor DNA (ctDNA) in Patients With Late-stage Breast Cancer

ACTDNA
Start date: December 1, 2016
Phase:
Study type: Observational

This is a retrospective, observational, multi-center clinical study of circulating tumor DNA (ctDNA) application in late-stage breast cancers.

NCT ID: NCT04560270 Completed - Pancreatic Cancer Clinical Trials

CIrculating Tumor DNA for Monitoring Response to First Line Chemotherapy in Unresectable PANcreatic Cancer

Start date: April 25, 2016
Phase: N/A
Study type: Interventional

With an incidence of more than 11,600 new cases per year in France and an annual number of deaths close to the incidence rate, adenocarcinoma of the pancreas is a public health problem. The aim of this study is to assess the predictive value of response to the 1st line of chemotherapy of mutated KRAS ctDNA (circulating tumor DNA) in unresectable metastatic or locally advanced pancreatic adenocarcinomas.

NCT ID: NCT04456972 Completed - Endometrial Cancer Clinical Trials

Reliability and Interest of Circulating Tumor DNA in Endometrial Cancers.

Start date: June 19, 2020
Phase: N/A
Study type: Interventional

The recent histo-prognostic molecular discoveries of the TCGA (The Cancer Genome Atlas) have shed new light on the classification of endometrial carcinomas. After carrying out different types of high-throughput molecular analyzes on 373 endometrial carcinomas of different histological types, 4 major tumor subtypes could be identified, each with a different survival profile (the "ultra-mutated" group with POLE mutations, the "hypermuted" group with microsatellite instability (MSI), the "low number of copies" group, and the "high number of copies" group). This histomolecular classification is not yet directly transposable to clinical practice and tumor genetic characteristics have not had any direct therapeutic impact to date. The main objective of the study is to determine the concordance rate between molecular analysis of tumor tissue and that of cDNA in patients with endometrial cancer during treatment.

NCT ID: NCT03750175 Completed - Clinical trials for Colorectal Cancer Metastatic

OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer -

OPTIPAL-II
Start date: June 1, 2018
Phase:
Study type: Observational

The present study will investigate the feasibility and clinical value of using circulating tumor DNA as selection for anti-epidermal growth factor receptor treatment for metastatic colorectal cancer.

NCT ID: NCT02620527 Completed - Cancer Clinical Trials

Concordance Between ctDNA Assay and FoundationOne

Start date: November 2014
Phase:
Study type: Observational

Foundation Medicine Inc. (FMI) is interested in studying the concordance of genomic alterations between primary and/or metastatic surgical biopsies, and circulating tumor DNA (ctDNA) within different solid tumor types and has been developing an assay in order to do so.